S&P 500 2430! Biotech Turn Around?

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary to get the Weekly Monster Market Commentary and join the 3,180 subscribers getting it for FREE!

This Daily Commentary Is Availabe For $99 Per Year, Sign Up!

Another Record in S&P 500

The S&P 500 (SPX) continues its move higher, finishing the day at 2430. The index is now up about 8.5 percent in 2017.
^SPX Chart

^SPX data by YCharts

Forward EPS have been rising helping to bring forward PE multiples on both operating and as reported PEs lower. The forward PE on the S&P 500 is currently 17, and 16 on an operating basis.
S&P 500 P/E Ratio Forward Estimate Chart

S&P 500 P/E Ratio Forward Estimate data by YCharts


The current SPY ETF Dividend Yield compared to the 10-year (TLT) yield suggest equities are still relatively cheap compared to the 10-year.
SPY Dividend Yield (TTM) Chart

SPY Dividend Yield (TTM) data by YCharts

Biotech Coming Back?

Biotechs (IBB, XBI) also so showed cohttps://seekingalpha.com/symbol/IBB?s=ibbnsiderable strength today and a nice turn after taking a beating lately. With a nice reverse head-and-shoulder formation on the intra-day charts.
IBB Price Chart

IBB Price data by YCharts

Subscribe to the MCM Stock Market Commentary to get it weekly and join the 3,180 subscribers getting it for FREE!


It will be important to watch for follow through in the sector in the coming days. This sector has been missing from the market for the past 2 years. It will important if the sector comes back to life.
IBB Chart

IBB data by YCharts

Till tomorrow.

Premium Content Video:

Biotech Bounce- Higher It Goes?

Get This Daily Report Mail To Your In-Box

[wysija_form id=”2″]



Michael Kramer is the Founder and Portfolio Manager of Mott Capital Management LLC, a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendation made during the past twelve months. Past performance is not indicative of future performance.